Study links surgery medicines to the stomach tumor environment
Part of Cancer, Digestive system clinical trials.
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed locally advanced stomach (or stomach–esophagus junction) adenocarcinoma that can be surgically removed, with no distant metastases
- You’re 18 to 75 years old
- You can provide leftover tumor tissue after your usual diagnosis for special tumor-environment testing
- You plan to receive medicines during the perioperative (around-surgery) period
- Your overall health/activity level is ECOG 0 or 1 (generally fully active or limited but ambulatory)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving personalized follow-up treatment after stomach cancer surgery and chemotherapy can help prevent the cancer from coming back. The treatment plan is tailored based on how well the tumor responded to initial chemotherapy.
This trial collects tissue samples to study why some stomach cancers become resistant to treatment. It aims to better understand how tumors and their surroundings interact, which could help doctors choose the right therapy for each patient.
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests if surgery to remove visible cancer in the belly combined with heated chemotherapy placed directly into the abdomen can help people with stomach cancer that has spread to the lining of the belly. It is for patients who are well enough to undergo major surgery and meet specific health requirements.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Gastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.